3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase NA
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
18
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Interventions
Mammography
12
Radiofrequency Ablation
9
Blood Specimen Collection
9
Standard of Care
8
Drug Delivery Systems
8
Colonoscopy
8
Uterine Myomectomy
6
Robotic Surgical Procedures
6
Cryosurgery
6
Colposcopy
6
Biopsy
6
Proton Therapy
5
Inositol
5
Therapeutics
4
Surgical Procedures, Operative
4
Radiotherapy
4
Leukapheresis
4
Food
4
Drug Therapy
4
Cryotherapy
4
Cisplatin
4
CF regimen
4
Brachytherapy
4
pegylated granulocyte colony-stimulating factor
3
exemestane
3
epigallocatechin gallate
3
Uterine Artery Embolization
3
Sunitinib
3
Paclitaxel
3
Oxaliplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
INDUSTRY
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled